Varian Medical Systems

Cellino Announces Ed Tekeian as Senior Vice President of Engineering

Retrieved on: 
Monday, March 18, 2024
Health, Stem Cells, Genetics, Other Health, General Health, Biotechnology, Software as a service, Computer science, Sample, 3M, Tufts University, Patient, Brontes Technologies, SVP, Radiosurgery, 3D, Software, Senior, Varian Medical Systems, Regenerative medicine, Multimedia, FDA, Nursing

Cellino Biotech, Inc. , a preclinical biotechnology company building an autonomous biomanufacturing platform for personalized regenerative medicine, today announced the expansion of its executive leadership team with the addition of Ed Tekeian as Senior Vice President of Engineering.

Key Points: 
  • Cellino Biotech, Inc. , a preclinical biotechnology company building an autonomous biomanufacturing platform for personalized regenerative medicine, today announced the expansion of its executive leadership team with the addition of Ed Tekeian as Senior Vice President of Engineering.
  • View the full release here: https://www.businesswire.com/news/home/20240318321537/en/
    Ed Tekeian, SVP of Engineering at Cellino (Photo: Business Wire)
    “We are thrilled to welcome Ed, who will bring deep multidisciplinary engineering leadership experience, in addition to strong acumen developing products used by hundreds of thousands of patients,” said Matthias Wagner, Co-Founder & Chief Technology Officer, Cellino.
  • Prior to joining Cellino, Ed was the Head of Software at Formlabs, where he led an integrated software team in developing user-facing applications for 3D printing.
  • Ed holds an MS in Computer Science from Tufts University.

Beckman Coulter Diagnostics Appoints Kevin O'Reilly as New President

Retrieved on: 
Tuesday, February 6, 2024
Bachelor of Engineering, Bachelor, Varian Medical Systems, Institute of technology, Marketing, Electricity, Radiation therapy, Trinity College

BREA, Calif., Feb. 6, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced Kevin O'Reilly's appointment as its new president succeeding Julie Sawyer Montgomery, who is now vice president and group executive, Danaher Diagnostics.

Key Points: 
  • BREA, Calif., Feb. 6, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced Kevin O'Reilly's appointment as its new president succeeding Julie Sawyer Montgomery, who is now vice president and group executive, Danaher Diagnostics.
  • "Kevin brings more than 30 years of leadership experience, including accelerating and delivering innovation on a global scale within the healthcare industry," said Sawyer Montgomery.
  • Kevin's experience running a complex operating division as president, coupled with his track record of achieving results equips him well to lead Beckman Coulter Diagnostics' next chapter."
  • "Every hour around the world, more than a million clinical samples – representing up to a million people – are analyzed using Beckman Coulter Diagnostics platforms," said O'Reilly.

Siteman Cancer Center Begins Treatment with Latest Mevion Proton Therapy System

Retrieved on: 
Thursday, November 16, 2023
Research, Hospitals, Health Technology, Radiology, Health, University, Science, Education, Oncology, Proton, Lung, Neck, NCI-designated Cancer Center, Brain, Radiation, Proton therapy, Head, Barnes-Jewish Hospital, Risk, FLASH, Intensity, Hospital, Scan (company), Varian Medical Systems, Breast cancer, NCI, Patient, Multimedia, Heart, IGRT, Image-guided radiation therapy, Metal toxicity, MLC, 3D, Professor, Medical imaging, Pharmaceutical industry

Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO.

Key Points: 
  • Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO.
  • View the full release here: https://www.businesswire.com/news/home/20231116635095/en/
    The MEVION S250i Proton Therapy System (Photo: Business Wire)
    Siteman Cancer Center is an NCI-designated Comprehensive Cancer Center that draws patients from Missouri, Southern Illinois and beyond.
  • “Our team also looks forward to advancing FLASH dosimetry research.”
    This latest system incorporates Mevion's cutting-edge HYPERSCAN® Pencil Beam Scanning for Intensity Modulated Proton Therapy (IMPT) with a proton MLC, along with an advanced 3D imaging system for high-precision Image-Guided Radiation Therapy (IGRT) and adaptive therapy.
  • These latest capabilities are the result of a collaborative effort between Mevion and Siteman Cancer Center, initiated in 2019.

Global Leader Advancing Cancer Treatment, Dr. Christel Smith, Joins Fuse Oncology as Chief Technology Officer

Retrieved on: 
Monday, November 20, 2023
GPU, Medicine, Research, Physics, Breast cancer, Patient, Radiation therapy, Product management, Flash, Varian Medical Systems, Elekta, University, Software, Cancer, UCSD, Management, Medical imaging, Fuse, Varian

BOONE, N.C., Nov. 20, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a trailblazing leader in radiation oncology software solutions, is pleased to announce the appointment of Dr. Christel Smith as its new Chief Technology Officer. An accomplished physicist and product innovator with a diverse background spanning physics, medicine, and technology, Dr. Smith joins the Fuse team with a wealth of experience and a passion for revolutionizing cancer care.

Key Points: 
  • BOONE, N.C., Nov. 20, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a trailblazing leader in radiation oncology software solutions, is pleased to announce the appointment of Dr. Christel Smith as its new Chief Technology Officer.
  • Dr. Smith's exceptional background in developing software that elevates oncology practices and improves cancer treatment across the globe makes her a valuable addition to the Fuse Oncology team.
  • As the new Chief Technology Officer, Dr. Smith will play a crucial role in advancing the company's mission to transform cancer care through technology.
  • "I am honored to join the Fuse Oncology team, where my passion for physics and my commitment to cancer care innovation converge," said Dr. Smith.

Mevion Selected to Equip BayCare’s Proton Therapy Center in Tampa

Retrieved on: 
Friday, November 3, 2023
Medical Devices, Hospitals, Health, Radiology, Oncology, Proton, Science, IGRT, Center of excellence, Laboratory, Central Florida, Heart, Varian Medical Systems, FLASH, Winter Haven Hospital, Cancer Institute, DECT, FIT, Franciscan Sisters of Allegany, Internal medicine, Hospital, Proton therapy, MLC, CT, Stroke, Neurosurgery, Fred J. Ansfield, Franciscan Sisters, Cancer, ARC, BayCare Ballpark, Patient, Intensity, Scan (company), Morton Plant Hospital, Medical imaging, Nursing, Tampa Bay

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is pleased to announce it has been selected by BayCare to equip the St. Joseph’s Hospital Cancer Institute in Tampa with a MEVION S250-FIT Proton Therapy System™*.

Key Points: 
  • Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is pleased to announce it has been selected by BayCare to equip the St. Joseph’s Hospital Cancer Institute in Tampa with a MEVION S250-FIT Proton Therapy System™*.
  • “BayCare is bringing an advanced proton radiation therapy center to Tampa so patients in our community don’t have to drive to Orlando or beyond to get this level of high-quality care.”
    The MEVION S250-FIT Proton Therapy System is thoughtfully designed to expedite proton therapy project timelines with a compact footprint, reduced construction requirements, and accelerated installation process.
  • “We are dedicated to advancing proton therapy technology and access, and I look forward to making a meaningful difference to patients and families across West Central Florida.”
    *The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.
  • Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy.

Mevion and RaySearch: A Synergy of Innovation Transforming Proton Therapy

Retrieved on: 
Monday, October 2, 2023
Technology, Research, Medical Devices, Health Technology, Software, Radiology, Health, Science, Oncology, Proton, Partnership, Proton therapy, RaySearch Laboratories, Radiation, FLASH, Algorithm, Varian Medical Systems, Neoplasm, Medical imaging

The collaboration leverages both companies’ domain expertise in the advancement of innovative solutions for HYPERSCAN IMPT, adaptive therapy, proton arc therapy, and FLASH proton therapy.

Key Points: 
  • The collaboration leverages both companies’ domain expertise in the advancement of innovative solutions for HYPERSCAN IMPT, adaptive therapy, proton arc therapy, and FLASH proton therapy.
  • Mevion has integrated in-room diagnostic CT imaging on the MEVION S250i and MEVION S250-FIT platforms to optimize the use of adaptive therapy.
  • Proton arc therapy: Arc therapy is an emerging proton therapy treatment delivery technique that optimizes rotational techniques of a gantry or upright patient positioner to conform and precisely target a tumor from multiple angles.
  • We are committed to breaking down technological and clinical access barriers to superior proton therapy technology.”
    Johan Löf, Founder and CEO of RaySearch, states, “RaySearch’s expertise in oncology software and Mevion Medical Systems’ latest technological advancements will continue to bring innovation in the proton therapy field and we look forward to working together with Mevion to further advance proton cancer treatments.”
    *The MEVION S250-FIT Proton Therapy System™, FLASH therapy, online adaptive therapy, and Arc therapy are not yet available for clinical use.

Mevion Launches “Mevion Capital” to Provide Customized Proton Therapy Funding Solutions for Healthcare Communities in US and Canada

Retrieved on: 
Sunday, October 1, 2023
Radiology, General Health, Health, Oncology, Varian Medical Systems, Cancer, Hospital, Radiation, Patient, Proton therapy, Medical imaging

In a healthcare landscape with growing budgetary constraints and reduced access to funding, Mevion Capital offers tailored financial solutions for the proton therapy industry.

Key Points: 
  • In a healthcare landscape with growing budgetary constraints and reduced access to funding, Mevion Capital offers tailored financial solutions for the proton therapy industry.
  • It aims to empower healthcare communities to upgrade existing radiation oncology services or establish new cancer centers with Mevion’s cutting-edge compact proton therapy technology.
  • Mevion Capital, in conjunction with Mevion's innovative compact proton therapy technology and end-to-end comprehensive solutions, is spearheading a paradigm shift.
  • We commit to reducing the financial barriers the healthcare communities may face to enable them to incorporate Mevion's compact proton therapy technology."

Re-Imagine Proton Therapy: Mevion Breaks Down Barriers at ASTRO 2023

Retrieved on: 
Thursday, September 28, 2023
Radiology, Biotechnology, Oncology, General Health, Health, Medical Devices, Health Technology, Other Health, Proton, Proton therapy, Health care, ASTRO, FIT, Radiation, ARC, Multimedia, Research, LINAC, FLASH, Patient, Cost, Annual general meeting, Varian Medical Systems, Entrepreneurship, Thomas Rockwell Mackie, Society, Clinical, Medical imaging

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, will showcase products and solutions to re-imagine proton therapy by breaking down access barriers at the upcoming American Society of Radiation Oncology 65th Annual Meeting (ASTRO 2023).

Key Points: 
  • Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, will showcase products and solutions to re-imagine proton therapy by breaking down access barriers at the upcoming American Society of Radiation Oncology 65th Annual Meeting (ASTRO 2023).
  • View the full release here: https://www.businesswire.com/news/home/20230928893588/en/
    Mevion Booth #2435 at ASTRO 2023 (Photo: Business Wire)
    Key highlights from Mevion at the ASTRO 2023 Annual Meeting will include:
    Breaking Site and Cost Barriers: Mission Complete - FIT Proton Therapy in your LINAC Vault
    The MEVION S250-FIT Proton Therapy System™ is the world’s first proton therapy system designed to FIT in a conventional LINAC vault.
  • We have scaled proton therapy down in size and reduced costs and barriers of entry, making proton therapy more accessible to patients.”
    Mevion proton therapy experts will be available at Mevion Booth #2435 to explore ideas that expand access to proton therapy treatment technology in your community during the ASTRO 65th Annual Meeting on October 1-3, 2023 in San Diego, CA.
  • *The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.

IPG Photonics Announces Addition to its Board of Directors

Retrieved on: 
Tuesday, August 1, 2023
Proton, IPG, Regents of the University of Colorado, University, Chairperson, Psychology, Medical physics, Varian Medical Systems, Radiation therapy, ICU Medical, Growth

MARLBOROUGH, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (Nasdaq: IPGP) today announced that its Board of Directors has elected Kolleen Kennedy as a new director of the company, increasing the size of the Board to 11 members.

Key Points: 
  • MARLBOROUGH, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (Nasdaq: IPGP) today announced that its Board of Directors has elected Kolleen Kennedy as a new director of the company, increasing the size of the Board to 11 members.
  • “I am pleased to welcome Ms. Kennedy to the Board,” said John Peeler, non-executive Chair of the Board.
  • “Ms.
  • Ms. Kennedy has served as a member of the board of ICU Medical, Inc., manufacturer of medical technologies, since 2021.

ETQ Announces Winner and Finalists of 2023 Innovation Excellence Awards, Showcases Ingenuity in Quality Management System

Retrieved on: 
Monday, June 19, 2023
NCM, Communication, QMS, Office of Inspector General, U.S. Department of Health and Human Services, Health, Workflow, Agriculture, Cancer, Varian Medical Systems, Transport, Federal Motor Carrier Safety Administration, Nutrien, DOT, Caesars Forum, CMV, Varian, Trane Technologies, FDA, Safety, Software, Pharmaceutical industry, Risk management, Hexagon

BURLINGTON, Mass., June 19, 2023 /PRNewswire/ -- ETQ, part of Hexagon, the leading quality management system (QMS) provider, today announced the 2023 winner and finalists for its annual ETQ Innovation Excellence Awards. ETQ customer, Trane Technologies, was selected for the winning project submission, followed closely by submissions from finalists Varian Medical Systems and Nutrien.

Key Points: 
  • BURLINGTON, Mass., June 19, 2023 /PRNewswire/ -- ETQ, part of Hexagon, the leading quality management system (QMS) provider, today announced the 2023 winner and finalists for its annual ETQ Innovation Excellence Awards.
  • ETQ customer, Trane Technologies, was selected for the winning project submission, followed closely by submissions from finalists Varian Medical Systems and Nutrien.
  • The Innovation Excellence Awards were presented during the company's annual Quality Vision customer conference, which took place live at Caesars Forum in Las Vegas last week.
  • Customers are not only driving value from ETQ Reliance today, but they constantly explore how they can improve future business results.